Cholestech Names Barbara McAleer to Position of Vice President of Quality and Regulatory Affairs
2/2/2005 6:30:11 AM
HAYWARD, Calif., Feb 02, 2005 /PRNewswire-FirstCall via COMTEX/ -- Cholestech Corporation (CTEC) today announced that Barbara McAleer has joined Cholestech as Vice President of Quality and Regulatory Affairs. Ms. McAleer brings to Cholestech over 20 years of experience in the healthcare industry, recognized for her success in the areas of quality, operations, compliance and management.
"Cholestech is committed to providing all our customers high quality product that they can rely on. Bringing the quality function to the executive level is further evidence of that commitment," said Warren E. Pinckert II, president and chief executive officer of Cholestech. "Barb brings to Cholestech significant experience in building world-class quality organizations. I look forward to working with her as we continue our focus on quality and customer service."
Ms. McAleer has been working as a managing partner at LOL Partners, a consulting firm specializing in the healthcare industry. Previously, Barb was Vice President of Operations and Quality for Calypte Biomedical Corporation, a manufacturer of HIV diagnostic kits. Previous to that position, she was the General Manager of Calypte's Rockville, Maryland operations. While at Calypte, Ms. McAleer was credited with significantly improving overall product margin through process improvements and cost savings.
Before joining Calypte, Ms. McAleer spent 18 years with Johnson & Johnson, starting out first in their Ethicon unit in positions within its manufacturing area, moving to the quality assurance area within Vistakon and ultimately becoming its Director of Quality Assurance. Following Vistakon, Ms. McAleer moved to the Lifescan division first as the Senior Director and then Vice President of Quality Assurance, where she redesigned Lifescan's quality systems to significantly improve compliance status.
Cholestech intends to grant Ms. McAleer a non-qualified stock option to purchase up to 40,000 shares of its common stock, pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv). The option's exercise price will be set at the next board meeting and will be equal the closing price of the Company's stock on The NASDAQ Stock Market on the day of the board meeting. It will have a seven-year term and vest monthly over four years, subject to continued employment with the Company.
About Cholestech
Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver function at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) and GDX(TM) Systems to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes.
Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at .cholestech. com.
SOURCE Cholestech Corporation
Warren E. Pinckert II, President and Chief E
Gruß
C.O
|
1 |
... |
156 |
157 |
|
159 |
160 |
...
| 203
Thread abonnieren
ere dinge. primacom z.b ;O) mein durchschnitt liegt derzeit bei 1,58 ;O)
